dc.contributor.author
Cantarero, David
dc.contributor.author
Ocaña, Daniel
dc.contributor.author
Onieva-García, María Ángeles
dc.contributor.author
Rodríguez-García, Juan
dc.contributor.author
Gálvez, Paulina
dc.contributor.author
Méndez, Cristina
dc.contributor.author
Crespo Palomo, Carlos
dc.contributor.author
López-Ibáñez de Aldecoa, Alejandra
dc.date.issued
2025-02-19T12:34:37Z
dc.date.issued
2025-02-19T12:34:37Z
dc.date.issued
2023-08-14
dc.date.issued
2025-02-19T12:34:37Z
dc.identifier
https://hdl.handle.net/2445/218975
dc.description.abstract
A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Elsevier B.V.
dc.relation
Reproducció del document publicat a: https://doi.org/10.1016/j.vaccine.2023.07.016
dc.relation
Vaccine, 2023, vol. 41, num.36, p. 5342-5349
dc.relation
https://doi.org/10.1016/j.vaccine.2023.07.016
dc.rights
cc-by-nc-nd (c) Elsevier B.V., 2023
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Genètica, Microbiologia i Estadística)
dc.subject
Vacuna antipneumocòccica
dc.subject
Anàlisi cost-benefici
dc.subject
Pneumococcal vaccine
dc.subject
Cost effectiveness
dc.title
Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
